CO2022014598A2 - Composiciones y métodos para el direccionamiento de c9orf72 - Google Patents
Composiciones y métodos para el direccionamiento de c9orf72Info
- Publication number
- CO2022014598A2 CO2022014598A2 CONC2022/0014598A CO2022014598A CO2022014598A2 CO 2022014598 A2 CO2022014598 A2 CO 2022014598A2 CO 2022014598 A CO2022014598 A CO 2022014598A CO 2022014598 A2 CO2022014598 A2 CO 2022014598A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- c9orf72
- addressing
- compositions
- systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991403P | 2020-03-18 | 2020-03-18 | |
| PCT/US2021/022840 WO2021188729A1 (en) | 2020-03-18 | 2021-03-17 | Compositions and methods for the targeting of c9orf72 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014598A2 true CO2022014598A2 (es) | 2022-10-31 |
Family
ID=75478206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014598A CO2022014598A2 (es) | 2020-03-18 | 2022-10-14 | Composiciones y métodos para el direccionamiento de c9orf72 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240309344A1 (enExample) |
| EP (1) | EP4121535A1 (enExample) |
| JP (1) | JP7847853B2 (enExample) |
| KR (1) | KR20230002401A (enExample) |
| CN (1) | CN116096885A (enExample) |
| AU (1) | AU2021237633A1 (enExample) |
| BR (1) | BR112022018673A2 (enExample) |
| CA (1) | CA3172178A1 (enExample) |
| CO (1) | CO2022014598A2 (enExample) |
| IL (1) | IL296477A (enExample) |
| MX (1) | MX2022011460A (enExample) |
| WO (1) | WO2021188729A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| EP4423263A4 (en) * | 2021-10-29 | 2026-03-04 | Mammoth Biosciences Inc | EFFECTOR PROTEINS, COMPOSITIONS, SYSTEMS, DEVICES, KITS AND METHODS FOR THERECOMMENDATION |
| US20250011766A1 (en) * | 2021-11-09 | 2025-01-09 | Prime Medicine, Inc. | Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis |
| US20250313819A1 (en) * | 2022-05-12 | 2025-10-09 | The Regents Of The University Of California | Therapeutic crispr/cas9 gene editing approaches to the c9orf72 repeat expansion mutation in ipscs |
| WO2023235725A2 (en) * | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| EP4536819A1 (en) | 2022-06-07 | 2025-04-16 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| EP4536286A1 (en) * | 2022-06-08 | 2025-04-16 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2023240157A2 (en) * | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| EP4665848A2 (en) * | 2023-02-15 | 2025-12-24 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2025024285A1 (en) * | 2023-07-21 | 2025-01-30 | Mammoth Biosciences, Inc. | Compositions for the modification of the human c9orf72 gene |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
| EP3374494A4 (en) | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
| CA3009308A1 (en) * | 2015-12-23 | 2017-06-29 | Chad Albert COWAN | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
| JP2019532644A (ja) * | 2016-09-30 | 2019-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｒｎａ誘導型核酸修飾酵素及びその使用方法 |
| US11773409B2 (en) | 2017-04-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors |
| AU2018264996A1 (en) * | 2017-05-09 | 2019-12-05 | University Of Massachusetts | Methods of treating Amyotrophic Lateral Sclerosis (ALS) |
| WO2019030306A1 (en) * | 2017-08-08 | 2019-02-14 | Depixus | ISOLATION AND IN VITRO ENRICHMENT OF NUCLEIC ACIDS USING SITE-SPECIFIC NUCLEASES |
| WO2019084148A1 (en) * | 2017-10-25 | 2019-05-02 | Monsanto Technology Llc | TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES |
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
-
2021
- 2021-03-17 MX MX2022011460A patent/MX2022011460A/es unknown
- 2021-03-17 BR BR112022018673A patent/BR112022018673A2/pt unknown
- 2021-03-17 JP JP2022556229A patent/JP7847853B2/ja active Active
- 2021-03-17 IL IL296477A patent/IL296477A/en unknown
- 2021-03-17 CN CN202180034169.7A patent/CN116096885A/zh active Pending
- 2021-03-17 CA CA3172178A patent/CA3172178A1/en active Pending
- 2021-03-17 AU AU2021237633A patent/AU2021237633A1/en active Pending
- 2021-03-17 EP EP21718316.9A patent/EP4121535A1/en active Pending
- 2021-03-17 KR KR1020227035510A patent/KR20230002401A/ko active Pending
- 2021-03-17 WO PCT/US2021/022840 patent/WO2021188729A1/en not_active Ceased
-
2022
- 2022-09-16 US US17/932,798 patent/US20240309344A1/en active Pending
- 2022-10-14 CO CONC2022/0014598A patent/CO2022014598A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021237633A1 (en) | 2022-10-06 |
| JP2023518541A (ja) | 2023-05-02 |
| CA3172178A1 (en) | 2021-09-23 |
| IL296477A (en) | 2022-11-01 |
| WO2021188729A1 (en) | 2021-09-23 |
| MX2022011460A (es) | 2022-12-15 |
| KR20230002401A (ko) | 2023-01-05 |
| BR112022018673A2 (pt) | 2022-12-27 |
| JP7847853B2 (ja) | 2026-04-20 |
| CN116096885A (zh) | 2023-05-09 |
| US20240309344A1 (en) | 2024-09-19 |
| EP4121535A1 (en) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231177A1 (es) | Composiciones y metodos para el direccionamiento de bcl11a referencia cruzada a solicitudes relacionadas | |
| PE20231178A1 (es) | Sistemas crispr tipo v clase 2 disenados por ingenieria | |
| BR112022018673A2 (pt) | Composições e métodos para o direcionamento de c9orf72 | |
| MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
| MX2022012677A (es) | Compuestos y metodos para modular el empalme. | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| CO2022009248A2 (es) | Anticuerpos anti-cd73 y usos de estos | |
| PH12021550843A1 (en) | Nucleic acid constructs and methods of use | |
| CO2022015925A2 (es) | Compuestos y métodos para modular el corte y empalme | |
| BR112019027750A2 (pt) | Bibliotecas transcriptônicas de célula única altorendimento, e métodos de fabricação e de usos | |
| SA523441205B1 (ar) | التحرير المتعدد للجينوم | |
| MX2020010974A (es) | Composiciones y métodos para la edición de genes. | |
| EP4585692A3 (en) | Methods for targeted insertion of dna in genes | |
| MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
| CL2020002973A1 (es) | Casetes de expresión de a- glucosidasa de ácido optimizado con codón y métodos de uso del mismo | |
| MX2021014368A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
| MX2019007765A (es) | Mutantes de algas de productividad elevada que tienen antena fotosintetica reducida. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| BR112016007727A8 (pt) | célula hospedeira, e, método para produzir uma proteína n-glicosilada. | |
| MX2021014528A (es) | Metodos y composiciones para generar alelos dominantes usando edicion del genoma. | |
| PH12018500568B1 (en) | Antisense nucleic acid | |
| CO2022001977A2 (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| MX2024000277A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| CO2017011617A2 (es) | Agentes nucleósidos para la reducción de la actividad perjudicial de los genes que contienen repeticiones de nucleótidos extendidas | |
| MX382997B (es) | Composiciones y metodos para mejorar la expresion genetica de pklr. |